Vertex Pharmaceuticals and Mammoth Biosciences, a Brisbane, California-based genetic research company, announced a new collaboration for the development of in vivo gene therapies for rare diseases using Mammoth’s ultra-small CRISPR systems.
Over the past couple of years, Mammoth Biosciences, the
On October 6, 2021, Voyager Therapeutics and Pfizer entered into a license option agreement, which allows Pfizer to exercise options to license Voyager’s adeno-associated virus (AAV) capsids for gene therapies.
Voyager is a Massachusetts-based company developing AAV-based gene therapies. The
On September 13, 2021, Regenxbio, a Maryland biotech company, and AbbVie announced that they have entered an agreement to develop and commercialize a potential gene therapy drug developed by Regenxbio for treating age-related macular degeneration (wet AMD), diabetic retinopathy, and
Following the successful development (and financial success) of its mRNA vaccine, biotech company Moderna is now looking to expand into the gene editing field. During a second-quarter earnings call on August 5, 2021, Moderna executives expressed that the company is
Caribou Biosciences, Inc., a Berkeley, California-based CRISPR genome-editing biopharmaceutical company, raised $304M in an initial public offering, one of the most lucrative IPOs in gene-editing. In June 2021, Gene editing biotech Verve raised $267M in IPO proceeds and later added
On July 15, 2021, American Gene Technologies (AGT), a Maryland biotech company, announced that the safety data in its Phase 1 trial of AGT103-T revealed no adverse effect. Based on the data, the FDA’s Data and Safety Monitoring Board (DSMB)
mRNA pioneer BioNTech announced recently that it is developing an mRNA-based vaccine to attempt to eradicate malaria. Its efforts are geographically focused on Africa, and the company said it is furthering those efforts to build manufacturing capacity on the African
On July 13, 2021, Prime Medicine, a Massachusetts biotech company developing next generation gene editing technology, emerged from stealth mode with $315 million in financing. The financing includes a $115 million Series A and a $200 million series B investment.
In today’s world, e-commerce and online visibility are sine qua non for success. Businesses are willing to invest considerable sums to boost their online presence and maximize sales. Because of this digitalization of business, domain names acquired incredible value. And
